Speakers
- Josh Baltzell
-
- Director
Split Rock Ventures - Josh Baltzell is a Managing Director at Split Rock Partners and has been
with the firm since its inception in June 2004. Split Rock Partners
is a venture firm focused on early stage investments in health care and
software. From 2002 to 2004, Mr. Baltzell was with St. Paul Venture
Capital. Prior to joining St. Paul Venture Capital, Mr. Baltzell was
an investment banker at Piper Jaffray, where he focused primarily on mergers and
acquisitions in the medical device sector. Mr. Baltzell also held various
marketing and business development positions with SCIMED/Boston Scientific.
Mr. Baltzell holds a B.A. in Economics from St. Olaf College and an M.B.A.
from the University of Minnesota’s Carlson School of Management.
- Mike Bates
-
- Former CFO
St. Francis Medical - Mike has more than 25 years of experience in corporate financial management
and currently serves as Director and Audit Committee Chairman of Emphasys Medical,
BARRX Medical and Satiety Inc. From 2005 to early 2007, Mike was Chief Financial
Officer of St. Francis Medical Technologies. St Francis was a medical device
company that developed a minimally invasive device and procedure to treat lumbar
spinal stenosis, a degenerative spine disease, that was acquired by Kyphon in
January 2007 for $725 million. In addition to the St. Francis success, Mike
has contributed to successful investor outcomes in his three previous companies.
He served as Vice President of Finance and Administration & CFO for Silicon Genetics,
acquired by Agilent Technologies; Collagen Aesthetics, Inc., acquired by Inamed
Corporation; and Penederm Incorporated, a publicly-traded specialty pharmaceutical
company acquired by Mylan Laboratories. Mike is a certified public accountant,
having begun his career at Deloitte and Touche LLP. He is a graduate of
California State University at Hayward and received an MBA in Finance from the
University of California at Berkeley.
- Mike Berman
-
- Medical Device Venture Catalyst
Berman Medical
- Ashley Boam
-
- Acting Deputy Director for Science & Review Policy
Office of Device Evolution, FDA - Ashley Boam currently serves as Acting Deputy Director for Science and Review Policy in
the Office of Device Evaluation at FDA's Center for Devices and Radiological Health.
Ms. Boam earned her B.S.E and M.S.B.E. in biomedical engineering from Tulane University
and the University of Alabama at Birmingham, respectively. She joined the FDA in 1993
as a scientific reviewer in the Division of Ophthalmic and ENT Devices. In 2002,
she joined the Division of Cardiovascular Devices as Chief of the Interventional
Cardiology Devices Branch. As acting Deputy Director for ODE, Ms. Boam provides
oversight of premarket review policies and procedures, including the review of RFDs
for combination products; acts as liaison to the Offices of Compliance, and Science
and Engineering Laboratories; and provides oversight for the 513g and ODE guidance programs.
- John J. Booth
-
- Chief Executive Officer
Spineology - John Booth has been a board member of Spineology since its inception in 1998
and was named CEO in September 2004. Prior to joining Spineology,
Mr. Booth held various executive level positions with Phillips Plastics
Corporation, serving as its CEO in 2001 and 2002. Before serving as
CEO of Phillips, he was CEO of Microvena Corporation, a cardiovascular
device subsidiary of Phillips from 1998 till 2001. Prior to joining
Phillips, Mr. Booth was President and CEO of INCSTAR Corporation, a publicly
held medical technology company involved in in-vitro diagnostics.
He has held various positions in both financial and general management
in the medical technology industry since 1981. Mr. Booth received
a BS degree in accounting from Villanova University and an MBA from
Seton Hall University.
- Mark J. Brooks
-
- Managing Director
ScaleVP - Mark J. Brooks, Managing Director, leads investments in healthcare services,
medical devices and drug development companies, and holds board seats with
Alimera Sciences, Inc., E-surg.com, IPC, LivHome, Inc., National Healing Holding
Corporation and Spinal Kinetics, Inc. He also is a Board Observer with Sylantro
Systems Corporation. His successful investments include Cardiac Pathways,
Cygnal Integrated Products, Rita Medical and U.S. Healthworks.
Prior to joining ScaleVP in 1995, Mark was a Senior Associate with Mercer Management Consulting, where he led projects in the healthcare and telecommunications sectors. Before joining Mercer, he served as a Loan Officer in the Media Group of Manufacturers Hanover Trust Company.
Mark holds a B.A. in Economics from Dartmouth College and an M.B.A. in Finance and Entrepreneurial Management from The Wharton School at the University of Pennsylvania.
- James W. Bullock
-
- President and Chief Executive Officer
Atritech, Inc. - James W. Bullock serves as President and Chief Executive Officer of Atritech,
Inc., a clinical stage medical device company that has developed a minimally
invasive device designed to prevent embolic events originating from the left
atrial appendage in patients with atrial fibrillation.
Prior to joining Atritech in 2005, Mr. Bullock served as President and Chief Executive Officer of Endocardial Solutions, Inc. from May 1994 until its acquisition by St. Jude Medical in February 2005. From April 1992 until joining Endocardial Solutions, Mr. Bullock served as President and Chief Operating Officer of Stuart medical, Inc., a cardiac monitoring start-up company. From April 1990 to April 1992, Mr. Bullock served as Vice President of Sales and Marketing of the Stackhouse Division of Bird Medical Technologies, a medical device company. From 1978 to 1990, Mr. Bullock served in a variety of marketing and sales management positions, most recently as Vice President of Sales, for the Pharmaseal Division of Baxter International, Inc. Mr. Bullock has served on the Board of Directors of several private medical device companies.
- Peter Claude
-
- Partner, Lifesciences
PricewaterhouseCoopers - Peter Claude, a Partner in PricewaterhouseCoopers’ Pharmaceutical
and Life Sciences Advisory Services Group, and has extensive advisory
experience serving a number of clients in the pharmaceutical,
biotechnology and medical devices industries in US and Europe,
including a four-year tour of duty in Switzerland. His engagement
experience has included corporate integrity agreement services,
customer contracting compliance and process reviews, compliance
program and privacy program assessments, including EU Safe Harbor,
sales and marketing risk assessments, government price reporting,
Pre-Clinical and GCP compliance risk assessments, compliance
auditing engagements, and strategic alliance advisory services.
Peter has published several studies on improving the reputation
of the pharmaceutical industry and on compliance risk management
better practices in the medical device industry. He is a frequent
speaker on the above topics at industry conferences and on webinars.
- Chad Cornell
-
- Director, Corporate Development
Medtronic, Inc. - Chad Cornell is Director of Corporate Development for Medtronic, Inc. Chad has
responsibility for supporting Medtronic’s CardioVascular business unit (vascular
therapies and cardiac surgery therapies), as well as other strategic initiatives
within Medtronic. Chad works in partnership with executive and business unit
management in evaluating and executing mergers and acquisitions, strategic alliances,
joint ventures, minority investments, technology licenses, divestitures and other
strategic transactions. Chad also assists in Medtronic’s strategic planning process.
Prior to joining Corporate Development, Chad was Legal Counsel – M&A, responsible for advising Corporate Development on strategic transactions across Medtronic. Chad began his career with Medtronic in 2003. Prior to joining Medtronic, Chad spent approximately five years as an associate attorney at Sidley & Austin in Chicago, Illinois working on mergers and acquisitions and securities offerings.
Chad received his undergraduate degree in Accounting from Marquette University and a Juris Doctorate from the University of Pennsylvania. Chad has also successfully completed Certified Public Accountant and Chartered Financial Analyst examinations.
- Ted Davis
-
- Vice President, Business Development
Wright Medical Technology - Ted Davis joined Wright Medical as Vice President – Business Development
in December 2006. Prior to joining Wright, Ted spent 10 years in the
life sciences venture capital field, where he served on various boards of
privately held medical device and biotechnology companies. Most recently,
he was a Partner with MB Venture Partners (MBVP), a $75 million, Memphis,
TN based firm focused on investments in medical technology and life sciences
with a specialization in musculoskeletal diseases. Prior to joining MBVP
in 2004, Ted spent seven years with Vector Fund Management (VFM), a
$240 million healthcare and life sciences focused venture capital fund
in Deerfield, IL. Prior to becoming a venture capitalist, Ted working
in the healthcare management consulting and pharmaceutical industries.
Ted received a Bachelor of Engineering degree in Biomedical Engineering
from Vanderbilt University and an MBA from the J.L. Kellogg Graduate
School of Management at Northwestern University.
- John A. Deedrick
-
- Managing Director
AMV Partners - John A. Deedrick, 46, is a Co-founder and Managing Director for Accuitive
Medical Ventures, an early stage medical device venture capital fund.
As of January 2008, Accuitive has over $230 million in capital under management
in its two medical device venture capital funds. Accuitive has a proprietary
relationship with The Innovation Factory (TIF), a medical device incubator
located in Duluth, GA. John serves as a Director for Accuitive’s investments
in MyoScience and Softscope. Prior to joining Accuitive Medical Ventures,
John was a Venture Manager for Mayo Medical Ventures. During his time at Mayo,
John managed investments in several emerging medical companies including Exact
Sciences (NASDAQ), Circe Biomedical (acquired), Ascension Orthopedics, Image-Guided
Neurologics (acquired by MDT), TomoTherapy (NASDAQ) and Volcano Therapeutics (NASDAQ).
In addition, he was instrumental in the start-up of four Mayo-founded
companies: Santarus (NASDAQ), Copharos, TeraMedica and Torax Medical.
He is also co-founder, Chairman and President of GreatDeeds, a Minnesota
non-profit organization. Prior to joining Mayo, John spent 12 years
in numerous operating roles within Honeywell and Alliant Techsystems.
John holds a B.S. in Business Administration from Northwestern College and an M.B.A. from St. Thomas University.
- Mark DuVal
-
- President
DuVal & Associates, P.A. - Mark E. DuVal, JD is President of DuVal & Associates, where he counsels both
mature and venture-backed pharmaceutical, medical device, and biotech companies
in the United States and Europe in addition to working extensively with combination
products. DuVal regularly advises clients in all areas of FDA law and regulation,
from product development, clinical trials, inspections and recalls to reimbursement
and compliance issues and post-marketing responsibilities. He specializes in
counseling medical device and pharmaceutical companies in the development and
implementation of strategic and tactical sales and marketing plans that are
appropriately aggressive, yet compliant.
- Jerome R. Edwards
-
- Founder
Veran Medical Technologies, Inc. - Prior to founding and financing Veran Medical Technologies, Edwards led product
development efforts with Surgical Navigation Technologies, Sofamor Danek, and
Medtronic helping develop the Medtronic StealthStation Navigation product — now
the standard of care in cranial, spine, and ENT surgery generating close to $175MM
annually. Jerome also earned Medtronic’s Technical Contributor of the Year
award for bringing the LocaLisa Intracardiac Navigation product to market for Atrial
Fibrillation Ablation. Edwards holds a B.S. in Engineering from the Colorado
School of Mines and an M.B.A. in Finance from Vanderbilt University.
Jerome has also completed studies in biomedical entrepreneurship at
Stanford University. Jerome has over five issued and pending patents
in his name. Edwards immigrated to the U.S. from Sri Lanka in 1984.
Email: jerome.edwards@veranmedical.com
- Richard Ferrari
-
- Co-Founder
DeNovo Ventures - Mr. Ferrari is a Co-Founder of De Novo Ventures which has $650 million
under management and which is one of the premier firms dedicated to
Medical Devices and Bio-Technology. Additionally, Rich has been a
successful CEO of two publicly traded medical technology companies.
Cardiovascular Imaging Systems, the first and leading developer of
ultrasound imaging catheters which was eventually acquired for
$125 million by Boston Scientific. His most recent success,
CardioThoracic Systems (CTS), the market leader in disposable
instruments and systems for performing minimally invasive beating
heart bypass surgery, was acquired by Guidant for $350 million in
November 1999. Rich was a co-founder of CTS and the force that led
the company to an initial public offering in only 7 months, the fastest
of any medical technology company in history. Mr. Ferrari also Co-Founded
the Medical Technology Group which spun-out Integrated Vascular Systems,
acquired by Abbot Vascular and Ensure, acquired by J&J.
Previously Mr. Ferrari held the positions of Executive Vice President and General Manager of ADAC Laboratories. In 1996 he founded Saratoga Ventures, a venture capital partnership that has provided seed financing to startup medical technology companies. Mr. Ferrari is the recipient of the Mallinckrodt Award for Excellence in Medicine and has been a finalist for the Entrepreneur of the Year Award. Rich holds a BS degree from Ashland University and an MBA from the University of South Florida.
- Glen French
-
- Co-Founder & Director
Asthmatx, Inc.
- Kelli Hallas
-
- Vice President, Reimbursement Services
Emerson Consultants, Inc.
- Sami Hamadé
-
- Partner
Aberdare - Sami Hamadé joined Aberdare as a Partner in 2006. Prior to Aberdare, Sami was
Vice President at the Guidant Corporation and head of the Compass Group, where he was
responsible for Guidant's venture capital and M&A activities. Additionally,
Sami led the West Coast Business Development unit which was composed of business
development groups from Vascular Intervention, Cardiac Surgery and Endovascular
Solutions divisions. Previous to this, Sami played founding roles in the
launch and development of significant businesses for Guidant including coronary
stents, carotid and peripheral systems. Sami began his career in medical
devices at Advanced Cardiovascular Systems.
Sami has been active in the medical device field for the last 15 years. He holds a Bachelors degree in Engineering from the American University of Beirut, a Masters Degree in Engineering from the University of Michigan, Ann Arbor and an MBA from the Stanford Graduate School of Business.
- Jay Hare
-
- Partner
PricewaterhouseCoopers - Jay Hare is one of five partners in PricewaterhouseCoopers’ Twin Cities Technology
Industry practice. This market leading practice includes technology companies
ranging from venture backed to the Fortune 500. Jay’s focus is technology
businesses primarily in the sectors of software and life sciences. He is an
Audit Partner. Jay has been involved in PwC's MoneyTree Venture Captial Survey
for the last ten years tracking quarterly trends and commenting on these trends to
the Minneapolis/St Paul Star Tribune.
- William (Bill) Harrington
-
- Partner
Three Arch Partners -
Following medical school, Bill did his postgraduate training in internal
medicine and diagnostic and interventional radiology at University of California,
San Francisco. Before joining Three Arch, he practiced as an interventional
radiologist for nine years, and maintains a clinical faculty appointment at
University of California, San Francisco. He has broad experience with a
wide variety of medical devices, minimally invasive surgical procedures,
and related clinical trials. He was a founder of Bay Medical Management.
Bill received his BS in Biology and Chemistry from Tufts University where he graduated summa cum laude. He obtained his MD from Harvard Medical School. He completed his MBA at the Haas School of Business at the University of California, Berkeley. Bill is a CFA charter holder.
Bill sits on the boards of Opus Medical, Reliant Technologies, Satiety, BioNeuronics, VetCentric and Metrika, among others.
- Jim Hickey
-
- President & CEO
Myocor, Inc.
- Ross Jaffe
-
- Managing Director
Versant Ventures
Accepting on behalf of Insulet
- B. Kristine Johnson
-
- President
Affinity Capital Management - Kris is President of Affinity Capital Management and a Managing General
Partner of Affinity Ventures III and IV, L.P. Previously she was Senior
Vice President and Chief Administrative Officer of Medtronic, Inc.
During her seventeen years at Medtronic she was also President and General
Manager of Medtronic’s Vascular business and President and General Manager
of its Tachyarrhythmia Management business. Kris received her BA from
St. Olaf College. She serves on the boards of directors of several
portfolio companies and non-profit organizations.
- Jack J. Kelley III, PhD
-
- Director of Advanced Concept Development
BD Medical Surgical Systems - Jack J. Kelley III, PhD is the Director of Advanced Concept Development
at BD Medical Surgical Systems in Franklin Lakes, NJ. Dr. Kelley
is responsible for technology and product innovation across the Medical
Surgical Systems business unit in Becton Dickinson, which has 11 product
categories that combined total over $2 Billion in annual sales. In his
career Dr. Kelley has held leadership positions in increasing levels of
responsibility in multiple areas including research and development,
business development, and strategic marketing.
Prior to joining BD, Dr. Kelley worked at Medtronic where he negotiated and managed co-development, co-marketing agreements and minority investments with medical device and pharmaceutical companies. Prior to Medtronic, he worked on mergers and acquisitions at the healthcare and biotech investment banking arm of JP Morgan. He has prepared, assessed, and made investment recommendations on business plans for several large institutional venture capital investors in the medical device space.
Prior to his industrial career, Dr. Kelley held a dual faculty appointment as a Research Assistant Professor at Dartmouth College, Departments of Chemistry and Computer Science. He holds an MBA from the University of Michigan, a Doctorate in Biophysical Chemistry from Dartmouth College, and a Bachelors degree in Chemistry from Marquette University.
- Michael J. Kolar
-
- Co-Chair Medical Technology Industry Group
Oppenheimer Wolff & Donnelly LLP - Michael Kolar serves as co-chair for Oppenheimer’s Medical Technology Industry Group.
He represents a wide variety of private and public clients in securities, financing,
merger and acquisition, general corporate and licensing matters. Mr. Kolar’s
experience includes private placement and venture capital financing, representation
of issuers and underwriters in public equity and debt offerings, private and public
company mergers, acquisitions and joint ventures, and technology licensing and e-commerce
matters. He also regularly assists clients with issues relating to executive
and equity-based compensation, and is a member of the National Association of Stock
Plan Professionals.
Mr. Kolar received a J.D. degree, summa cum laude (valedictorian), from William Mitchell College of Law, and a bachelor of business administration degree from the University of Notre Dame.
- Curt LaBelle, M.D.
-
- Vice President
Investor Growth Capital, Inc.
- Shelly Wall Lanning
-
- Managing Director
HealthCor Partners - In November 2007 Shelly joined HealthCor Partners, a $300MM healthcare private
equity fund based in New York City. Shelly spent the previous 6.5 years
on the New York healthcare investment team at MSVP where she focused primarily
on Medical Device and Biotechnology investing. Ms. Wall was at Director
of National Healing Corporation, Medsite, and Trivirix International and was
involved with pSivida, D-Pharm, and Solstice Neuroscience.
Shelly has spent her career in the life sciences field, in strategic, operating and investment roles. Prior to joining Venture Partners, she was a Senior Associate and Kauffman Fellow at Tullis-Dickerson & Co, an early- stage healthcare venture capital firm. Prior to the fellowship program, she worked on silicone breast implant litigation focusing on regulatory compliance, product development and manufacturing for medical devices. Her experience includes working in operations for an orthopedic medical device company and as a biotech research analyst at an investment management company.
Shelly earned her M.B.A. in finance from The Wharton School at the University of Pennsylvania. She holds a degree in Physiology from the University of Minnesota.
- Brad Lehrman
-
- Partner--Venture Attorney
Lommen, Abdo, Cole, King & Stageberg
General Partner – Portage Equity Investments II, LP
- Gerald Mattys
-
- CEO
Tactile Systems Technology, Inc.
- Mary McGrory-Usset
-
- Founder
The Mendota Company
- Trevor Moody
-
- General Partner
Frazier Healthcare
- Phil E. Nalbone
-
- Sr. Research Analyst
RBC Capital Markets - Phillip E. Nalbone is a Managing Director of Equity Research at RBC Capital
Markets in San Francisco, where he leads a team responsible for coverage of
the medical devices and diversified medical products sectors.
He has been a sell-side analyst specializing in the medical technology industry
for more than 16 years, and during that time has covered nearly 80 companies at
all levels of market capitalization and has participated in nearly 40 equity
financings. In July of 2005, Bloomberg Markets Magazine named Phil to its
list of "50 Top Analysts in America" and No. 1 in the Health Care Products category.
Prior to joining RBC in May of 2002, he had been the senior medical products and
hospital supplies analyst at Salomon Smith Barney since 1999. Between 1995-1999,
he was a partner at Volpe, Brown, Whelan & Co. He began his career as a medical
devices analyst in 1992 with Hambrecht & Quist in New York. Phil is a graduate
of St. Lawrence University, where he was elected to Phi Beta Kappa.
- Kevin L. Nickels
-
- President and CEO
Celleration
- Gordie Nye
-
- Managing General Partner
Prism VentureWorks - A pivotal member of Prism's life sciences investment team, Gordie focuses on
medical device, specialty pharma and breakthrough diagnostics. He currently
sits on the board of Aptus Endosystems, Aritech, CoAxia, Insulet, iScience
and is the Chairman of Myocor. Prior to joining the firm in 2003, Gordie
served as CEO of REVA Medical, Inc., the developer of a novel resorbable,
drug-eluding stent for the interventional market. REVA is currently in a
strategic alliance with Boston Scientific (BSX) to complete its pilot
human clinical trial, an initiative that represents a potential major
advancement in interventional cardiology.
- Barb Peterson
-
- Founder & President
Emerson Consultants, Inc.
- Rick Randall
-
- President and CEO
TranS1 - Rick Randall is the President and CEO of TranS1, Inc, a company dedicated to
developing and marketing minimally invasive therapies to treat lower back pain.
Mr. Randall served as President and CEO of Innovasive Devices, Inc. from 1994 to 2000, when the firm was acquired by the Ethicon Division of Johnson & Johnson. Innovasive Devices was a developer, manufacturer and marketer of arthroscopic surgical products.
From 1989 to 1996, Mr. Randall served as President, Chairman and Director of Target Therapeutics, Inc., a medical device company serving the interventional neurosurgery market. Target was acquired by Boston Scientific, Inc in 1997. Prior to Target, Mr. Randall held various sales and marketing management positions with Trimedyne, Inc., Baxter Edwards and the USCI Division of C.R. Bard, Inc.
Mr. Randall is also co-founder of Conceptus, Inc. and Cardima, Inc. Mr. Randall is a Director of AbbeyMoor Medical and TissueLink Medical.
Mr. Randall earned a Bachelor of Science degree from State University College at Buffalo, Buffalo, NY.
- John Seaberg
-
- CEO
NeoChord
- Steve Shapiro
-
- Technology Partner
Galen Associates & Advanced Technology Ventures
- David Shaw
-
- VP Business Development and General Counsel
Hansen Medical
- Zubeen Shroff
-
- Managing Director
Galen Associates - Mr. Shroff is a Managing Director of Galen Partners, a leading healthcare private
equity firm founded in 1990. Prior to joining Galen in 1997, Mr. Shroff was
a Principal at The Wilkerson Group, with a client base including pharmaceutical,
diagnostic, device and biotech companies, plus a select number of venture capital
firms. He played a major role in developing several of The Wilkerson Group’s
practice areas, including outcomes research, strategy formulation, and disease
management initiatives. Mr. Shroff was formerly at Schering-Plough France,
where he directed the marketing, sales and Phase IV clinical development of the
company’s high-growth biotech business.
Mr. Shroff currently serves on the board of directors of several Galen portfolio companies including Aperio Technologies, National Rehabilitation Equipment, ONI Medical Systems, Pet DRx, and Tactile Systems. He is an Executive Committee member of Boston University’s Medical School Advisory Board and a member of the Westchester Medical Center Foundation Board.
Mr. Shroff earned a M.B.A. from the Wharton School and a B.A. biological science from Boston University.
- Jon Snyder
-
- Venture Partner
Arboretum Ventures
- Michael Stroup
-
-
Director, Healthcare Investment Banking – Medical Technology Group
RBC Capital Markets - Michael Stroup is a Director in the Healthcare Investment Banking – Medical
Technology group at RBC Capital Markets. Mr. Stroup has over 14 years of
healthcare experience. Prior to joining the firm, Mr. Stroup worked for
the Corporate Finance divisions of JPMorgan H&Q and Prudential Securities,
and provided strategic consulting to hospital systems, physician networks
and health plans with Mercer’s Healthcare Provider Consulting Practice.
Mr. Stroup received a Bachelor of Arts from the University of Michigan
and a MBA with a focus in Health Care Management and Finance from the
Wharton School at the University of Pennsylvania.
- John P. Sullivan
-
- Associate
Foundation Medical Partners - Mr. Sullivan has over twelve years of operating experience in the health care
industry, with a focus on medical devices and biotechnology. Before joining
Foundation, he helped start Molecular Staging Inc., a venture-backed biotechnology
company spun out of the Yale School of Medicine, serving as Director of Business
Development. Prior to MSI, Mr. Sullivan led the development of the first coronary
stent at SCIMED/Boston Scientific Corporation as Senior Product Manager. He holds
a B.S. in Industrial Engineering degree with distinction from Stanford University
and an M.B.A. from the Stanford University Graduate School of Business.
Email: Jsullivan@foundmed.com
- Mark Wagner
-
- Co-Founder
Orasi Medical - Mark Wagner's career in MedTech has spanned nearly 30 years including 15 years
with GE Healthcare and three years with Nellcor. He has been a CEO of
multiple companies in the Twin Cities over the last 15 years. Notable
successes include the sales of Survivalink (Automated External Defibrillators)
at five times revenue and ProVation Medical (Clinical software) at nine times
revenue. Under his leadership overall Venture Capital returns have averaged
5X invested capital. As a CEO or Board member, he has raised nearly $100M of
capital in the forms of venture equity, venture debt and strategic equity.
Most recently he co-founded and is Board Chairman of Orasi Medical, a spin-out
from the University of Minnesota, that is developing a diagnostic tool for
neurological diseases using data derived from Magnetoencephalography (MEG).
He recently joined the board of BioMedix.
- Kevin Wasserstein
-
- Managing Director
Versant Ventures - Kevin Wasserstein is a Managing Director at Versant Ventures, a leading
healthcare-focused venture capital firm targeting early-stage investments
across healthcare. Kevin brings more than fifteen years of venture
capital and operating experience in medical device and high technology companies,
and specializes in investing and building medical device companies from their
earliest seed or concept stages through their entire life cycle. Prior to
joining Versant in 2002, Kevin served in a variety of marketing and business
development roles at Guidant Corporation, including acting as the Director of
Marketing in Guidant's Cardiac Surgery Group, and serving in Guidant's Compass
Business Development Group, where he was involved in acquisition, licensing and
investment activities with both private and public medical device companies, and
in formulating corporate strategies to develop innovative medical technologies.
Kevin currently serves, or has served, in a variety of board or advisory roles
with companies which include: Acclarent, Cellutions, LipoSonix, NDO Surgical,
NeoGuide Systems, Rox Medical, Second Sight Medical, St. Francis Medical (sold)
and The Innovation Factory.
Kevin holds both Bachelor's and Master's degrees in Mechanical Engineering, as well as an MBA, all from Stanford University.
- Ralph Weinberger
-
-
Partner, Technology Industry Group
PricewaterhouseCoopers LLP - With over 24 years of service to life sciences and technology companies in the
Twin Cities and Greater Minnesota, Ralph has worked with clients ranging in
size from large global companies to high-growth small and mid-cap companies
focused on developing into a global force. In addition to coordinating
delivery of high quality accounting and auditing services to his clients, Ralph
has worked alongside his clients in addressing their needs for international
expansion, mergers and acquisitions and accessing the public and private debt and
equity markets. Ralph is also the Treasurer of the Minnesota High Tech Association.
Copyright © 2008 International Business Forum. All Rights Reserved.